Myeloma Archives - Loyal Conservatives

James McCaffrey Passes Away at 65 from Multiple Myeloma: Remembering the Iconic Performer of Max Payne

NEW YORK – American actor James McCaffrey has passed away at the age of 65 after a battle with multiple myeloma, a form of blood cancer, according to Variety. McCaffrey was best known for his work in the popular video game series Max Payne, where he voiced the title character, as well as for his role as Alex Casey in “Alan Wake 2.” Fans of McCaffrey, as well as colleagues in the film and gaming …

Hospice Utilization Trends Spiked for Multiple Myeloma Patients in US

Los Angeles, California – Multiple myeloma (MM) remains a challenging hematological malignancy with high morbidity and mortality rates. Despite advancements in treatment, many patients continue to face the grim reality of the disease. Understanding the Place of Death (POD) for MM patients is crucial in enhancing end-of-life care, support for caregivers, and managing the costs associated with caregiving. A recent study delved into trends in POD and hospice utilization for MM patients in the United …

FDA Panel Overwhelmingly Supports CAR-T Therapies for Multiple Myeloma Treatment

Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee discussed the risks and benefits of CAR-T therapies developed by Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee voted in support of Carvykti and Abecma as earlier lines of treatment, despite concerns about early deaths in the trials. During the meeting, experts evaluated the data from the trials, noting a higher rate of early deaths …

CAR-T Therapy Trials for Multiple Myeloma Face FDA Scrutiny After Early Deaths

Boston, MA – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T cell therapies in multiple myeloma patients. The trials in question involve Johnson & Johnson’s Carvykti and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma. CAR-T cell therapies have shown promise in treating certain types of cancer by genetically modifying a patient’s own immune cells to attack cancer cells. However, the FDA is now …

JNJ and LEGN FDA Meeting: Risks and Benefits of New Cancer Treatment for Multiple Myeloma Evaluated

Washington, DC – On Friday, the FDA’s Oncologic Drugs Advisory Committee is set to convene to review Johnson & Johnson and Legend Biotech Corporation’s supplemental biologics license application for Carvykti for the treatment of relapsed or refractory multiple myeloma. The discussion will focus on the efficacy and safety of ciltacabtagene autoleucel, also known as cilta-cel, in patients who have undergone at least one prior line of therapy. One key point of contention will be the …

Side Effects Spike: Regeneron’s ‘Best-in-Class’ Myeloma Drug Causes 100% Adverse Reactions

Houston, TX – A new study on Regeneron’s myeloma drug has revealed significant side effects, with 100% of participants experiencing adverse reactions. The drug, described as ‘best-in-class’ by researchers, is drawing attention for its powerful impact on multiple myeloma patients. The clinical trial, conducted in Houston, TX, involved a diverse group of patients with varying degrees of the disease. Despite the promising results in terms of efficacy, the high incidence of side effects raises concerns …

CAR-T: Multiple Myeloma Patients See Hopeful Advances!

NEW YORK CITY, New York – Groundbreaking treatment for multiple myeloma cancer has reached a 90 percent effectiveness rate, offering hope to patients like Judith Harding and Bill McHugh. Both individuals were able to defy the odds and enjoy more fulfilling lives than expected after being diagnosed with multiple myeloma. Thanks to recent treatment advances, multiple myeloma patients can now realistically dream of a disease-free life. For example, Dr. Sundar Jagannath of the Icahn School …